首页> 外文期刊>Trials >Efficacy of post-procedural oral hydration volume on risk of contrast-induced acute kidney injury following primary percutaneous coronary intervention: study protocol for a randomized controlled trial
【24h】

Efficacy of post-procedural oral hydration volume on risk of contrast-induced acute kidney injury following primary percutaneous coronary intervention: study protocol for a randomized controlled trial

机译:术中口服水合体积对原发性经皮冠状动脉介入治疗后造影剂引起的急性肾损伤风险的功效:一项随机对照试验的研究方案

获取原文
           

摘要

Contrast-induced acute kidney injury (CI-AKI) contributes toward unfavorable clinical outcomes. Oral hydration with water is inexpensive and it may be effective in the prevention of CI-AKI, but its efficacy among patients undergoing primary percutaneous coronary intervention (PCI) remains unknown. Our study is a secondary analysis on the database from the ATTEMPT study. We enrolled ST-elevation myocardial infarction (STEMI) patients undergoing primary PCI. Eligible patients received peri-procedural aggressive (left ventricular end-diastolic pressure-guided) or routine (≤?500?mL) intravenous hydration with an isotonic solution (0.9% NaCl) with randomization. The primary endpoint was CI-AKI, defined as a??25% or 0.5?mg/dL increase in serum creatinine from baseline during the first 48–72?h post-procedurally. All patients drank unrestricted amounts of fluids freely, the volume of which was recorded until 24?h following primary PCI. Oral hydration volume/weight (OHV/W) ratios were calculated. The association between post-procedural oral hydration (quartiles) and CI-AKI was assessed using multivariable analysis controlling for confounders, including intravenous hydration strategies. Our study determined the effects of post-procedural oral hydration on CI-AKI following primary PCI, which is a potential strategy for CI-AKI prevention among patients with STEMI at very high risk. ClinicalTrials.gov, NCT02067195 . Registered on 21 February 2014.
机译:造影剂诱发的急性肾损伤(CI-AKI)导致不良的临床结果。口服水的价格便宜,并且可以有效地预防CI-AKI,但其在初次经皮冠状动脉介入治疗(PCI)患者中的功效尚不清楚。我们的研究是对ATTEMPT研究中数据库的辅助分析。我们招募了接受原发性PCI的ST抬高型心肌梗死(STEMI)患者。符合条件的患者随机接受等渗溶液(0.9%NaCl)的静脉水化,进行围手术期积极治疗(左心室舒张末期压力引导)或常规(≤?500?mL)静脉水化治疗。主要终点为CI-AKI,定义为术后48-72小时内血清肌酐较基线增加≥25%或0.5?mg / dL。所有患者自由畅饮无限制量的液体,直到初次PCI后24小时才记录其体积。计算了口服水合体积/重量(OHV / W)之比。手术后口服水合(四分位数)与CI-AKI之间的关联使用控制混杂因素的多变量分析进行了评估,包括静脉水合策略。我们的研究确定了原发性PCI后术后口服补水对CI-AKI的影响,这是预防高风险STEMI患者CI-AKI的潜在策略。 ClinicalTrials.gov,NCT02067195。 2014年2月21日注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号